Meeting
2014 ASCO Annual Meeting
Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.
Authors
Daniele Raggi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Daniele Raggi , Patrizia Giannatempo , Rosalba Miceli , Elena Farè , Nicola Nicolai , Luigi Piva , Davide Biasoni , Mario Catanzaro , Tullio Torelli , Silvia Stagni , Manuela Marongiu , Alessandro M. Gianni , Roberto Salvioni , Andrea Necchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4561)
DOI
10.1200/jco.2014.32.15_suppl.4561
Abstract #
4561
Poster Bd #
129
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Efficacy and safety of the ΑPE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia.
First Author: Catherine Lhomme
Poster
2013 ASCO Annual Meeting
A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer.
First Author: Sudeep Gupta
Poster
2012 ASCO Annual Meeting
Biweekly regimen of nonpegylated liposomal doxorubicin with cyclophosphamide, vincristine, and prednisone plus rituximab (R-COMP-14) as primary treatment for diffuse large B-cell lymphoma (DLBCL): Long-term follow-up of a phase II study.
First Author: Joaquin Herrero
Poster
2011 ASCO Annual Meeting
A single-center experience of EMA/CO chemotherapy for high-risk gestational trophoblastic neoplasia: Induction low-dose cisplatin and etoposide chemotherapy improves outcome.
First Author: C. Alifrangis